跳至主要内容
临床试验/NCT00806013
NCT00806013已完成不适用

Study the Effects of CYP2C9 and CYP2C19 Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Glipizide in Healthy Chinese Subject

Chinese Academy of Sciences1 个研究点 分布在 1 个国家目标入组 36 人开始时间: 2008年8月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
36
试验地点
1

研究概览

简要总结

The aims of this study were to investigate the effects of CYP2C9 and CYP2C19 polymorphisms on the pharmacokinetics and pharmacodynamics of glipizide in healthy Chinese subjects.

详细描述

Compared with CYP2C19, CYP2C9 polymorphism appears to have a dominant role in glipizide pharmacokinetics and pharmacodynamics in vivo. This indicated that dose adjustment based on CYP2C9 genotype may improve antidiabetic treatment.

研究设计

研究类型
Observational
观察模型
Case Control
时间视角
Prospective

入排标准

年龄范围
21 Years 至 27 Years(Adult)
性别
Male
接受健康志愿者

入选标准

  • nonsmokers and in good health

排除标准

  • family history of diabetes mellitus
  • taking any drug, alcohol, foods containing caffeine, or grapefruits and juice before study

研究者

申办方类型
Other Gov

研究点 (1)

Loading locations...

相似试验